FY2024 Earnings Forecast for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Research analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of G1 Therapeutics in a note issued to investors on Tuesday, June 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.56) per share for the year, up from their previous estimate of ($0.61). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for G1 Therapeutics’ Q4 2024 earnings at ($0.02) EPS, FY2025 earnings at ($0.03) EPS and FY2026 earnings at ($0.11) EPS.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC cut their price target on shares of G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $3.00 price target (down from $5.00) on shares of G1 Therapeutics in a research note on Monday.

G1 Therapeutics Price Performance

G1 Therapeutics stock opened at $2.25 on Thursday. The company has a fifty day simple moving average of $3.71 and a 200-day simple moving average of $3.59. G1 Therapeutics has a 12-month low of $1.08 and a 12-month high of $6.14. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34. The stock has a market cap of $117.63 million, a P/E ratio of -3.63 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $14.48 million for the quarter, compared to analysts’ expectations of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same period last year, the firm posted ($0.53) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Financial Advocates Investment Management acquired a new position in G1 Therapeutics in the fourth quarter valued at $39,000. SG Americas Securities LLC acquired a new position in shares of G1 Therapeutics during the first quarter worth about $58,000. Capstone Investment Advisors LLC acquired a new position in shares of G1 Therapeutics during the fourth quarter worth about $76,000. Jump Financial LLC acquired a new position in shares of G1 Therapeutics during the fourth quarter worth about $105,000. Finally, Choreo LLC acquired a new position in shares of G1 Therapeutics during the fourth quarter worth about $107,000. 24.21% of the stock is currently owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.